Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2022-08-15 |
2022-06 |
-0.55 |
N/A |
N/A |
N/A |
2022-05-13 |
2022-03 |
-0.63 |
N/A |
N/A |
N/A |
2022-03-31 |
2021-12 |
0 |
N/A |
N/A |
N/A |
2021-11-15 |
2021-09 |
-0.68 |
N/A |
N/A |
N/A |
2011-09-01 |
2011-06 |
0 |
N/A |
N/A |
N/A |
2011-06-04 |
2011-03 |
0 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2022-09-16 |
Morgan Stanley |
Upgrade |
|
Underweight |
2022-05-17 |
Morgan Stanley |
Upgrade |
|
Underweight |
2022-01-06 |
Morgan Stanley |
Downgrade |
Equal-Weight |
Underweight |
2021-12-22 |
Jefferies |
Downgrade |
Buy |
Hold |
2021-12-15 |
Morgan Stanley |
Downgrade |
Overweight |
Equal-Weight |
2021-12-15 |
Guggenheim |
Downgrade |
Buy |
Neutral |
Date |
Name |
Relation |
Quantity |
Description |
2021-08-09 |
ADIMAB, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security |
27.85M |
Conversion of Exercise of derivative security |
2022-08-18 |
ELIA MARC |
Director |
0.00 |
Purchase |
2021-08-09 |
GERNGROSS TILLMAN U. |
Chief Executive Officer |
0.00 |
Conversion of Exercise of derivative security |
2022-08-31 |
HERING DAVID |
Chief Executive Officer |
8.00K |
Purchase |
2021-08-09 |
MCGUIRE TERRANCE G |
Director |
0.00 |
Purchase |
2021-08-09 |
MITHRIL II, L.P. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2022-06-29 |
FMR, LLC |
15.23M |
70.68M |
14.00% |
2022-06-29 |
M28 Capital Management LP |
6.40M |
29.69M |
5.88% |
2022-06-29 |
Orbimed Advisors LLC. |
5.06M |
23.46M |
4.65% |
2022-06-29 |
Slate Path Capital, LP |
3.74M |
17.33M |
3.43% |
2022-06-29 |
683 Capital Management LLC |
3.60M |
16.72M |
3.31% |
2022-06-29 |
Vanguard Group, Inc. (The) |
3.30M |
15.32M |
3.03% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-07-30 |
Fidelity Growth Company Fund |
5.06M |
23.50M |
4.65% |
2022-06-29 |
Vanguard Total Stock Market Index Fund |
1.62M |
7.52M |
1.49% |
2022-06-29 |
Fidelity Growth Company K6 Fund |
1.33M |
6.18M |
1.22% |
2022-07-30 |
iShares Russell 2000 ETF |
1.24M |
5.74M |
1.14% |
2022-06-29 |
Fidelity Series Growth Company Fund |
1.23M |
5.71M |
1.13% |
2022-06-29 |
Vanguard Small-Cap Index Fund |
691.96K |
3.21M |
0.64% |